MegaSporeBiotic Study on Triglyceride Levels

Efficacy of Spore Forming Bacilli Supplementation in Patients with Mild to Moderate Elevation of Triglycerides:

A 12 week, Randomized, Double-Blind, Placebo Controlled Trial Andrew W. Campbell, MD; Drew Sinatra, ND; Zhiwei Zhang, PhD, Stephen T Sinatra, MD

A word about high triglyceride levels

Approximately 1/3 of the population has elevated triglyceride levels (>150 mg/dL) in the bloodstream, or hypertriglyceridemia (HT). In addition to cholesterol levels like LDL and HDL, elevated levels of triglycerides are also commonly used as indicators for heart disease risk.

Due to the metabolic functions of the gut microbiome, an imbalance of gut bacteria (gut dysbiosis) can increase serum tirglycerides by increasing intestinal permeability and allowing for bacterial endotoxin translocation into circulation.

Finally, excessive intake of certain dietary fat stimulates triglyceride production in the liver. as triglycerides circulate the body, they can contribute to plaque formation in arteries, fatty build-up around the liver, and systemic inflammation.

The Study of Spore Forming Bacilli Supplementation in Patients with Mild to Moderate Elevation of Triglycerides

This study examined the effects of gut microbiotia modulation, using MegaSporeBiotic, in reducing serum triglycerides. Researchers recruited 80 participants with non-fasting triglyceride levels greater than 150 mg/dL to complete the study.

The average baseline triglyceride levels were 207 mg/dL. Participants were randomly divided into 2 groups. The treatment group received two capsules of MegaSporeBiotic once daily, which was taken in the morning. The control group received a placebo pill containing rice flour. Triglyceride levels were measured at baseline, 6 weeks, and 12 weeks of the experiment.

Results indicated that non-fasting triglyceride levels dropped by 25% in just 6 weeks and a whopping 38% after 12 weeks of probiotic supplementation. This study highlights the efficacy of MegaSporeBiotic in reducing serum triglyceride levels.

The spore-based probiotic MegaSporeBiotic supplement contains 5 different spore forming bacilli:

  • Bacillus indicus
  • HU36
  • Bacillus subtilis HU58
  • Bacillus coagulans SC-208
  • Bacillus licheniformis
  • Bacillus clausii SC-109
Megasporebiotic Ingredients

Study design

The study was a randomized, double-blind, placebocontrolled study with eighty participants with non-fasting triglyceride levels greater than 150 mg/dL.

Conclusion

This study is the second publication on MegaSporeBiortic that demonstrates a significant reduction in serum triglyceride levels. Serum triglycerides are a critical end-point for a probiotic, as they illustrate the ability of the probiotic to conduct several critical metabolic functions in the microbiome.

Bacillus spore-based probiotics are gaining popularity due to their safety, survivability, and capacity to modulate the gut microbiome. Research continues to highlight the role of MegaSporeBiotic in supporting human health outcomes.

Rescources: 
1. Berglund L, Brunzell J, et al. Treatment options for hypertriglyceridemia: 
   from risk reduction to pancreatitis. Best Pract Res Clin Endocrinol Metab.
   2013;28(3):423-37.  

2. Tenenbaum A, Klempfner R, et al. Hypertriglyceridemia: a too long unfairly 
   neglected major cardiovascular risk factor. Cardiovasc Diabetol. 2014;13:159.

3. Welty F. How do elevated triglycerides and low HDL-cholesterol affect 
   inflammation and atherothrombosis? Curr Cardiol Rep. 2013;15(9):400.

4. LaRosa J. Triglycerides and coronary risk in women and the elderly. Arch 
   Intern Med. 1997;157:961–968.

5. Di Caro S, Tao H, et al. Bacillus clausii effect on gene expression pattern 
   in small bowel mucosa using DNA microarray analysis. Eur. J. Gastroenterol. 
   Hepatol 2005; 17 951–960.

6. Lefevre M, Racedo S, et al. Probiotic strain Bacillus subtilis CU1 stimulates
   immune system of elderly during common infectious disease period: a randomized, 
   double-blind placebo-controlled study. Immun. Ageing 2015; 1224.

7. Bader J., Albin A, et al. Spore-forming bacteria and their utilisation as
   probiotics. Benef. Microbes 2012; 3 67–75.

8. Elshaghabee F, Rokana N. et al. “Bacillus As Potential Probiotics: Status,
   Concerns, and Future Perspectives” Frontiers in microbiology vol. 8 1490;Aug.2017.

9. Patsch J, Miesenbock G,et al. Relation of triglyceride metabolism and coronary 
   artery disease. Studies in the postprandial state. Arterioscler Thromb.
   1992;12:1336–1345

10. Carr A, Samaras K, et al. Pathogenesis of hiv-1-protease inhibitor-associated   
    peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet.
    1998;351:1881–1883.

11. Ghoneim M, Hassan A, et al. Effect of polysaccharide from Bacillus subtilis sp.
    on cardiovascular diseases and atherogenic indices in diabetic rats. BMC
    Complement. Altern. Med 2016; 16:112.